Austar Lifesciences Ltd. released its earnings results on Aug 26, 2025. The company reported HK$0.052 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.052.

Is Austar Lifesciences Ltd. overvalued?

According to Wall Street analysts Austar Lifesciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Austar Lifesciences Ltd. pay dividends?

Austar Lifesciences Ltd. pays a Notavailable dividend of HK$0.05 which represents an annual dividend yield of N/A. See more information on Austar Lifesciences Ltd. dividends here

What is Austar Lifesciences Ltd.’s EPS estimate?

Austar Lifesciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Austar Lifesciences Ltd. have?

Austar Lifesciences Ltd. has 512,582,030 shares outstanding.

What happened to Austar Lifesciences Ltd.’s price movement after its last earnings report?

Austar Lifesciences Ltd. reported an EPS of HK$0.052 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.758%.

Which hedge fund is a major shareholder of Austar Lifesciences Ltd.?

Currently, no hedge funds are holding shares in HK:6118

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Austar Lifesciences Ltd. Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

4.40%

Trailing 12-Months

Asset Growth

-3.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Austar Lifesciences Ltd.

Austar Lifesciences Limited, an investment holding company, provides integrated engineering solutions to pharmaceutical manufacturers and research institutes in Mainland China and internationally. It operates through six segments: Liquid and Bioprocess System; Clean Room and Automation Control and Monitoring System; Powder and Solid System; GMP Compliance Service; Life Science Consumables; and Distribution and Agency of Pharmaceutical Equipment. The company offers liquid and bioprocess systems, including pharmaceutical water, and liquid preparation and bioprocess systems; powder and solid systems; clean utility equipment and systems; clean room, automation control, and monitor systems; and freeze-dryer, sterile filling, and visual inspection equipment. It also provides pharmaceutical process contamination control products; packaging and aseptic containment products; biosafety and lab animal equipment and consumables; laboratory one-stop solutions; and single-use bioprocess equipment and consumables. In addition, the company offers design, quality risk control, consulting, research and development support, process engineering, digitalization construction, after-sale, on-site, upgrading, relocation, and asset management services. Further, it is involved in the agency and distribution of pharmaceutical equipment, as well as provides assembly and pre-assembly services. The company was founded in 1991 and is headquartered in Shanghai, China.